On May 6, 2020, IGEA Pharma announced that an evaluation by the University of Miami Miller School of Medicine suggested that the IGEA’s COVID-19 antibody rapid test appeared to be superior to an established ELISA procedure in detecting IgM and IgG antibodies.

Furthermore, an overall higher sensitivity of the IGEA’s rapid test over the ELISA procedure used was observed using a RT PCR test comparison for the same specimens, and the PCR results comparison could suggest suitability in using the antibody-based test even in early stages of the infection.